Rigel Earnings Reports

Rigel reported record net product sales of $144.9 million, a 39% increase compared to 2023, and generated full-year net income of more than $17 million.

Rigel Pharmaceuticals reported a net income of $12.4 million for the third quarter of 2024, with total revenues of $55.3 million. The company's growth was driven by increased sales of TAVALISSE, REZLIDHIA, and GAVRETO, as well as contract revenue from collaborations.

Rigel Pharmaceuticals reported total revenues of $36.8 million for the second quarter of 2024, driven by record sales of TAVALISSE and REZLIDHIA, as well as the addition of GAVRETO to their commercial portfolio. The company reported a net loss of $1.0 million, approaching net income break even.

Rigel Pharmaceuticals reported Q1 2024 financial results, featuring strong commercial demand with record bottle sales for TAVALISSE and REZLIDHIA. Total revenues reached $29.5 million, with a net loss of $8.2 million, or $0.05 per share.

Rigel Pharmaceuticals reported a net income of $0.7 million for the fourth quarter of 2023, with total revenues of $35.8 million driven by TAVALISSE and REZLIDHIA sales and collaboration revenues.

Rigel Pharmaceuticals reported a net loss of $5.7 million on total revenues of $28.1 million for Q3 2023. Revenue was driven by TAVALISSE net product sales of $24.5 million and REZLIDHIA net product sales of $2.7 million.

Rigel Pharmaceuticals reported a net loss of $6.6 million for the second quarter of 2023, with total revenues of $26.9 million. TAVALISSE net product sales increased by 15% year-over-year, and the company continued to advance its development programs.

Rigel Pharmaceuticals reported a net loss of $13.5 million for the first quarter of 2023, with total revenues of $26.1 million. The company saw a 47% increase in net product sales compared to Q1 2022, driven by TAVALISSE and REZLIDHIA sales.

Rigel reported a net income of $1.4 million for the fourth quarter of 2022, with total revenues of $51.3 million, including sales of TAVALISSE® and REZLIDHIA™.

Rigel Pharmaceuticals reported a net loss of $19.0 million for the third quarter of 2022. Total revenues were $22.4 million, including $19.2 million in TAVALISSE net product sales, which increased by 20% compared to the same period in 2021.

Rigel Pharmaceuticals reported a net loss of $13.5 million for Q2 2022, with total revenues of $29.8 million. TAVALISSE net product sales increased by 9% to $18.6 million, and contract revenues from collaborations totaled $11.3 million.

Rigel Pharmaceuticals reported a net loss of $27.4 million for the first quarter of 2022. Total revenues were $16.7 million, including $16.2 million in TAVALISSE net product sales. TAVALISSE sales increased by 31% compared to the first quarter of 2021.

Rigel Pharmaceuticals reported a net loss of $22.6 million for the fourth quarter of 2021, with total revenues of $20.4 million, including $17.6 million from TAVALISSE net product sales and $2.8 million from contract revenues. The company's costs and expenses increased to $41.8 million due to research and development and commercial activities.

Rigel Pharmaceuticals reported a net loss of $21.0 million, or $0.12 per basic and diluted share, with total revenues of $21.5 million. TAVALISSE net product sales were $16.0 million, a decrease of 2% from the same period in 2020.

Rigel Pharmaceuticals reported a net loss of $13.8 million for the second quarter of 2021, with total revenues of $26.3 million, including TAVALISSE net product sales of $17.1 million.

Rigel Pharmaceuticals reported a net income of $39.5 million for the first quarter of 2021, with total revenues of $81.0 million. The company is advancing its clinical programs, including fostamatinib for COVID-19 and IRAK1/4 program.

Rigel Pharmaceuticals reported Q4 2020 financial results, including a net loss of $19.2 million, or $0.11 per share. Total revenues were $18.5 million, with TAVALISSE net product sales increasing by 28% to $17.8 million.

Rigel Pharmaceuticals reported third quarter total revenues of $18.4 million, including net product sales of $16.3 million, a 39% year-over-year increase. The company's net loss was $14.2 million, or $0.08 per share.

Rigel Pharmaceuticals reported second quarter results with net product sales of $15.0 million, a 47% year-over-year increase. The company experienced a net loss of $17.6 million, or $0.10 per share. They also appointed David Santos as Chief Commercial Officer and progressed their pipeline, including a Phase 2 trial for COVID-19 pneumonia.

Rigel Pharmaceuticals reported a net income of $21.2 million for the first quarter of 2020, with total revenues of $55.8 million, including $12.7 million in net product sales and $43.1 million in contract revenues from collaborations.

Rigel reported fourth quarter total revenues of $15.4 million, with net product sales of $13.8 million. The company's net loss for the quarter was $17.2 million, or $0.10 per share.